These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20086001)

  • 1. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
    Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
    Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
    J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
    Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
    J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
    Millward M; Underhill C; Lobb S; McBurnie J; Meech SJ; Gomez-Navarro J; Marshall MA; Huang B; Mather CB
    Br J Cancer; 2013 May; 108(10):1998-2004. PubMed ID: 23652314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
    Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
    Atzpodien J; Morawek L; Fluck M; Reitz M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of tremelimumab in patients with metastatic melanoma.
    Camacho LH; Antonia S; Sosman J; Kirkwood JM; Gajewski TF; Redman B; Pavlov D; Bulanhagui C; Bozon VA; Gomez-Navarro J; Ribas A
    J Clin Oncol; 2009 Mar; 27(7):1075-81. PubMed ID: 19139427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
    Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
    Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
    Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
    J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J
    Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
    Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
    Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.